Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome.
Publication/Presentation Date
9-1-2023
Abstract
Dravet syndrome (DS) is a monogenic, often refractory, epilepsy resultant from SCN1A haploinsufficiency in humans. A novel therapeutic target in DS that can be engaged in isolation or as adjunctive therapy is highly desirable. Here, we demonstrate reduced expression of the rodent glutamate transporter type 1 (GLT-1) in a DS mouse model, and in wild type mouse strains where Scn1a haploinsufficiency is most likely to cause epilepsy, indicating that GLT-1 depression may play a role in DS seizures. As GLT-1 can be upregulated by common and safe FDA-approved medications, this strategy may be an attractive, viable, and novel avenue for DS treatment.
Volume
10
Issue
9
First Page
1695
Last Page
1699
ISSN
2328-9503
Published In/Presented At
Hameed, M. Q., Hui, B., Lin, R., MacMullin, P. C., Pascual-Leone, A., Vermudez, S. A. D., & Rotenberg, A. (2023). Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome. Annals of clinical and translational neurology, 10(9), 1695–1699. https://doi.org/10.1002/acn3.51851
Disciplines
Medicine and Health Sciences
PubMedID
37452008
Department(s)
Medical Education
Document Type
Article